Custom Search

Monday, September 1, 2014

Antibodies successfully inhibit further infection of HIV

Broadly neutralizing antibodies against HIV successfully inhibit further infection of HIV.

A life saving treatment against HIV infection is not a dream now; it could be reality tomorrow, as researchers from National Institute of Allergy and Infectious Diseases (NIAID) USA have developed antibodies which are successful in inhibiting HIV from infecting new human CD4 cells.

Broadly neutralizing antibodies (bNAbs) are group of antibodies PGT121, VRC01 and VRC03.
These antibodies were administered to HIV patients who have discontinued drug therapy for various reasons including side effects of prolonged use and were found to keep viral load under control.

In an experimental model these antibodies (bNAbs) prevented HIV from infecting new CD4 cells derived from HIV negative donors in an invitro experimental model. These antibodies can be used in treating individuals who stop taking antiretroviral drugs, bNAbs can reduce the load of antiretroviral drugs and their side effects when combined with drug therapy.

No comments:

How to successfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.

1.You should write your Email ID in the box provided and push the subscribe button

2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Check our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.

Enter your email address get our articles by email whenever this website is updated

Delivered by FeedBurner

Join the list of our readers from Universities ,Research and
Development centers Pharmaceutical Companies from all over the world.

Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: Website:
Copyright © 2008-2020 all rights reserve